144results about How to "Promote angiogenesis" patented technology

Methods and devices for transmitting micromechanical forces locally to induce surface convolutions into tissues on the millimeter to micron scale for promoting wound healing are presented. These convolutions induce a moderate stretching of individual cells, stimulating cellular proliferation and elaboration of natural growth factors without increasing the size of the wound. Micromechanical forces can be applied directly to tissue, through biomolecules or the extracellular matrix. This invention can be used with biosensors, biodegradable materials and drug delivery systems. This invention will also be useful in pre-conditioned tissue-engineering constructs in vitro. Application of this invention will shorten healing times for wounds and reduce the need for invasive surgery.

The subject invention concerns non-degradable three dimensional porous collagen scaffolds and coatings. These scaffolds can be prepared around sensors for implantation into a body. A specific embodiment of the invention concerns implantable glucose sensors. Sensors comprising a collagen scaffold of the invention have improved biocompatibility by minimizing tissue reactions while stimulating angiogenesis. The subject invention also concerns methods for preparing collagen scaffolds of the invention. The subject invention also concerns sensors that have a collagen scaffold of the invention around the exterior of the sensor.

Methods and devices for the regulation of gene expression in tissue by applying an electric and/or electromagnetic field generated by specific and selective signals so as to treat diseases, conditions, and/or tissue. Gene expression is the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are described for the regulation of Vascular Endothelial Growth Factor (VEGF) protein gene expression in endothelial cells of various targeted tissues via the capacitive coupling or inductive coupling (e.g., by electrodes or one or more coils or other field generating devices disposed with respect to the targeted cells) of specific and selective signals to the cells of these tissues, where the resultant electric and/or electromagnetic fields treat diseased or injured tissues. The resulting methods and devices are useful for the targeted treatment of peripheral vascular disease, cardiovascular disease, macular degeneration, wound healing, tendon and ligament healing, in preventing tumor growth or spread, and other conditions in which VEGF protein may be implicated.

A catheter and methods for luminal therapy are provided wherein a catheter has an outer balloon with a multiplicity of apertures for infusing one or more therapeutic agents into a vessel wall, an intermediate balloon having a multiplicity of apertures offset from the apertures of outer balloon to serve as a baffle that reduces jetting and promotes uniform distribution of therapeutic agent exiting through the outer balloon, and an impermeable inner balloon disposed within the intermediate balloon that enables the intermediate and outer balloons to be forced into engagement with the vessel wall to dilate the vessel and disrupt plaque lining the vessel wall and to also facilitate the uniform delivery of the therapeutic agent. The outer balloon may include protrusions that contact the vessel wall to disrupt the plaque, bumpers to reduce washout during infusion of therapeutic agents; the intermediate balloon may include a texture, ribs or protrusions on its outer surface to prevent adhesion to the outer balloon during dilation of the vessel; and the catheter may include a guide wire lumen sized to accept an energy delivery device to delivery energy that enhances uptake of the therapeutic agent or prolongs therapeutic effectiveness of the agent.

The present invention relates to a pharmaceutical composition for promoting arteriogenesis, and preparation method and applications of the same, wherein said pharmaceutical composition comprises an effective amount of a drug, and a peptide hydrogel, and it forms a microenvironment for autologous cell recruitment and tissue regeneration.

Disclosed is a method and test kit to diagnose tumorigenicity or the presence of tumor cells in a patient by detecting the level of FBLN-3 expression or biological activity in the patient. Also disclosed are methods to identify regulators of tumor cell growth, motility and/or invasion, by identifying regulators of FBLN-3 expression or activity. Methods to identify anti-angiogenic and pro-angiogenic agents are also described, wherein such factors regulate the expression and/or activity of FBLN-3. Finally, the present invention relates to therapeutic methods and reagents for the inhibition of tumor growth and development and/or for the inhibition or promotion of angiogenesis, using FBLN-3, homologues and analogs thereof, and agents that modulate the expression and/or activity of FBLN-3.

The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.

The invention provides an undifferentiated anti-aging amplification culture medium for human umbilical cord/adipose tissue-derived stem cells. The problem in the prior art that a serum-free medium used for culturing mesenchymal stem cells is easy to differentiate and easily causes aging and apoptosis of adult stem cells is solved. The undifferentiated anti-aging amplification culture medium for human umbilical cord/adipose tissue-derived stem cells comprises cell factors, vitamins and chemical small molecules, and the culture system comprises multiple chemical small molecules and biomacromolecules and has the effects of improving physiological metabolism and proliferation and growth potential of cells, resisting oxidative stress response, scavenging free radicals, preventing DNA mutation, protecting mitochondria, reducing molecular wastes in the cells and activating longevity genes and telomerase.

The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated virases, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.

A bioreactor for the formation of mature blood cells from haematopoietic stem cells is disclosed. The bioreactor comprises a first zone and a second zone. The first zone and the second zone are separated by a first membrane. The first membrane allows the preferential passage of red blood cells relative to the haematopoietic stem cells and their 5 other progeny excluding red blood cells. The first membrane is formed by at least a separating layer and a porous layer, where the porous layer is in contact with the first zone, such that the haematopoietic stem cells can be grown in the porous layer. The bioreactor comprises a third zone. The first zone and the third zone are separated by a second membrane, and the second membrane allows the passage of nutrients from the 10 third zone to the first zone and the passage of metabolites of the cells from the first zone to the third zone, while substantially preventing the passage of growth factors from the first zone to the third zone.

A vaginal regeneration device is provided and method of promoting regeneration of vaginal tissue is provided. The method includes providing a patient having a vagina in need of vaginal tissue regeneration vaginal lubricant and a vaginal regeneration device. The vagina is lubricated and the regeneration device is inserted into the patient's vagina, wherein the vibrating mechanism is activated, allowing the vibrations to contact the vaginal wall for a therapeutic period of time. The device includes a shaft having a first end and a second end, a tapered insertion at said first end of said shaft and an end cap at said second end of the shaft, and a vibrating mechanism within the shaft. The invention further is directed to kits for promoting regeneration of vaginal tissue comprising at least two vaginal regeneration devices having different diameters along the majority of the length of the shaft.

Implants for treating insufficient blood flow to a heart muscle with transmyocardial revascularization are disclosed. Methods of treating insufficient blood flow to a heart muscle with the implant are also disclosed. The implant can have a body with an inner lumen that supports a channel in the heart muscle to allow for increased blood flow through the lumen upon implantation. The implant can include active agents to prevent or inhibit thrombotic closure of the channel, to promote vascularization, or both.

The present disclosure provides methods and uses of Tie2 agonists alone or in combination with antiviral agents. In particular, the present disclosure provides methods and uses for treating influenza, treating a bacterial superinfection associated with influenza and decreasing lung endothelial leakage. The disclosure also provides compositions comprising (a) a Tie2 agonist and (b) an antiviral agent and methods and uses thereof.

Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of stimulation. The present invention discloses that tPA is a specific PDGF-C activating protease, and that the CUB-domains in PDGF-CC directly interact with the protease, are required for efficient proteolysis, and released CUB-domains are tPA inhibitors. Preferably, the method and compositions of the present invention are used for simultaneously stimulating, or simultaneously inhibiting, thrombolysis and angiogenesis.

The invention discloses an alkylated chitosan multifunctional hydrogel as well as a preparation method and application thereof. The preparation method of the alkylated chitosan multifunctional hydrogel comprises the following steps: (1) preparing alkylated chitosan; (2) preparing an alkylated chitosan solution, and preparing a four-arm polyethylene glycol benzaldehyde solution; and (3) mixing thealkylated chitosan solution and the four-arm polyethylene glycol benzaldehyde solution, and performing gelatinization at room temperature. According to the method provided by the invention, an alkanechain is used to modify an amino group of chitosan to prepare the alkylated chitosan, the hydrophobic alkane chain and a hydrophobic cell membrane can be fixed to each other by hydrophobic interaction, so that blood cells can be fixed on the long chain of the chitosan, blood is coagulated, and bleeding is quickly stopped; and polyethylene glycol benzaldehyde is cross-linked through an imine bond to form the stronger-functional more-stable self-repairing hydrogel, and the hydrogel has the functions of concentrating the blood to stop bleeding, absorbing exudate, and promoting wound repair of a hydrogel.

The present invention provides polynucleotides and polypeptides (VECSM polynucleotides and polypeptides) that are differentially expressed in vascular endothelial cells. The invention further provides a variety of compositions, diagnostic, and therapeutic methods based on identification of these markers. In particular, the invention provides a targeting agent linked to a functional moiety, wherein the functional moiety can comprise any of a number of different agents, including imaging agents, cytotoxic agents, and stimulators or inhibitors of angiogenesis.

Patterned hydrogel arrays and methods of preparing patterned hydrogel arrays are disclosed. Advantageously, the methods used to prepare the patterned hydrogel arrays allow for controlling individual hydrogel spot conditions such as hydrogel spot modulus, hydrogel spot ligand identity and hydrogel spot ligand density, which allows for preparing a wide range of hydrogel spots in a single array format. Patterned hydrogel arrays can also be formed to include hydrogel-free pools surrounded by hydrogel. Additionally, the patterned hydrogel arrays of the present disclosure support the culture of a range of cell types. The patterned hydrogel arrays offer the ability to rapidly screen substrate components for influencing cell attachment, spreading, proliferation, migration, and differentiation.

Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are comprised of promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell.

In an embodiment of the present invention, a nutraceutical formula comprising a combination of chromium, zinc, berry extract, Polygonum cuspidatum extract, aloe vera, chlorophyll and L-arginine combined synergistically to reduce inflammation in mammals suffering from diabetes. In another embodiment of the present invention, a nutraceutical formula comprising a of zinc, chromium, berry extract, Polygonum cuspidatum extract, aloe vera, chlorophyll and L-arginine combined synergistically to enhance wound healing in mammals suffering from diabetes. In an alternative embodiment of the present invention, a nutraceutical formula comprising a of zinc, chromium, berry extract, Polygonum cuspidatum extractive, aloe vera, chlorophyll and L-arginine combined synergistically to reduce inflammation in mammals not suffering from diabetes. In another embodiment of the present invention, a nutraceutical formula comprising a combination of zinc, chromium, berry extract, Polygonum cuspidatum extractive, aloe vera, chlorophyll, and L-arginine combined synergistically to enhance wound healing in mammals not suffering from diabetes.

Cationic antimicrobial peptides (AMPs) are an integral part of the innate immune system. Cathelicidin and defensin homologs from a variety of species exhibit broad-range bactericidal activity. The human cathelicidin analog, hCAP18, is encoded by the CAMP gene. Vitamin D3 and its analogs upregulate transcription of CAMP and defensin B2 (defB2) genes, leading to increased expression of hCAP18 mRNA and defB2. Induction of CAMP was observed in acute myeloid leukemia (AML), immortalized keratinocyte and colon cancer cell lines, as well as normal human bone marrow (BM)-derived macrophages and fresh BM cells. The present invention provides methods of inducing cathelicidin production by administering Vitamin D3 or Vitamin D3 analogs, as well as methods of treating skin infections and infections of the colon, sepsis and wound healing, preventing bacterial growth on skin grafts, promoting angiogenesis, and promoting chemoattraction by administering Vitamin D3 or Vitamin D3 analogs to upregulate cathelicidin and defensin expression.